These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 19283890)

  • 1. Prolonged therapy for hepatitis C with low-dose peginterferon.
    Poynard T; Ratziu V
    N Engl J Med; 2009 Mar; 360(11):1152; author reply 1152-3. PubMed ID: 19283890
    [No Abstract]   [Full Text] [Related]  

  • 2. Prolonged therapy for hepatitis C with low-dose peginterferon.
    Koretz RL; Gluud C
    N Engl J Med; 2009 Mar; 360(11):1151; author reply 1152-3. PubMed ID: 19279350
    [No Abstract]   [Full Text] [Related]  

  • 3. Prolonged therapy for hepatitis C with low-dose peginterferon.
    Hoshida Y; Golub TR
    N Engl J Med; 2009 Mar; 360(11):1152; author reply 1152-3. PubMed ID: 19283891
    [No Abstract]   [Full Text] [Related]  

  • 4. [Chronic hepatitis C viral infection with persistent normal serum alanine aminotransferases].
    Huang CX; Bai XF
    Zhonghua Gan Zang Bing Za Zhi; 2005 Jan; 13(1):70-1. PubMed ID: 15670508
    [No Abstract]   [Full Text] [Related]  

  • 5. [Two-step interferon rebound therapy].
    Kato M; Yuki N; Iyoda K; Yamamoto K; Hayashi N
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):497-501. PubMed ID: 15359849
    [No Abstract]   [Full Text] [Related]  

  • 6. Viral kinetics during antiviral therapy in patients with chronic hepatitis C and persistently normal ALT levels.
    Puoti C; Bellis L; Castellacci R; Montagnese F
    Hepatology; 2005 Mar; 41(3):683; author reply 684. PubMed ID: 15723301
    [No Abstract]   [Full Text] [Related]  

  • 7. Biochemical and virological changes in serum of nonresponder or relapser chronic hepatitis C patients retreated with interferon and ribavirin followed by interferon alone.
    Cuccorese G; Tursi A; Spinazzola AM; Modeo ME; Miglietta A
    Am J Gastroenterol; 2000 Sep; 95(9):2399-400. PubMed ID: 11007262
    [No Abstract]   [Full Text] [Related]  

  • 8. The substantial role of initial ribavirin dose on the response to peginterferon alpha/ribavirin therapy in patients with genotype 1b chronic hepatitis C.
    Dai CY; Huang CF; Chuang WL; Huang JF; Yu ML
    Am J Gastroenterol; 2009 Sep; 104(9):2358-9. PubMed ID: 19727098
    [No Abstract]   [Full Text] [Related]  

  • 9. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C.
    Wirth S; Pieper-Boustani H; Lang T; Ballauff A; Kullmer U; Gerner P; Wintermeyer P; Jenke A
    Hepatology; 2005 May; 41(5):1013-8. PubMed ID: 15793840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The results of a randomized trial looking at 24 weeks vs 48 weeks of treatment with peginterferon alpha-2a (40 kDa) and ribavirin combination therapy in patients with chronic hepatitis C genotype 1.
    Brandão C; Barone A; Carrilho F; Silva A; Patelli M; Caramori C; Focaccia R; Pereira L; Pedroso M; Tatsch F; Pessoa M;
    J Viral Hepat; 2006 Aug; 13(8):552-9. PubMed ID: 16901286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effects of pegylated interferon and ribavirin in Korean patients with chronic hepatitis C virus infection].
    Kang MJ; Jung EU; Park SW; Choi P; Kim JH; Park SJ; Park ET; Lee YJ; Lee SH; Seol SY
    Korean J Hepatol; 2008 Sep; 14(3):318-30. PubMed ID: 18815455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: a report of 9 cases.
    Buti M; Valdés A; Sánchez-Avila F; Esteban R; Lurie Y
    Hepatology; 2003 May; 37(5):1226-7. PubMed ID: 12717407
    [No Abstract]   [Full Text] [Related]  

  • 14. Peginterferon alpha-2b plus ribavirin with or without amantadine [correction of amantidine] for the treatment of non-responders to standard interferon and ribavirin.
    Hasan F; Al-Khaldi J; Asker H; Al-Ajmi M; Owayed S; Varghese R; Siddique I; Al-Nakib B
    Antivir Ther; 2004 Aug; 9(4):499-503. PubMed ID: 15456080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients.
    Lawitz E; Rodriguez-Torres M; Muir AJ; Kieffer TL; McNair L; Khunvichai A; McHutchison JG
    J Hepatol; 2008 Aug; 49(2):163-9. PubMed ID: 18486984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peginterferon Alfa-2b and ribavirin for 12 versus 24 weeks in HCV infection.
    Henry MJ
    N Engl J Med; 2005 Sep; 353(11):1182-3; author reply 1182-3. PubMed ID: 16167381
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
    Sullivan SD; Jensen DM; Bernstein DE; Hassanein TI; Foster GR; Lee SS; Cheinquer H; Craxi A; Cooksley G; Klaskala W; Pettit K; Patel KK; Green J
    Am J Gastroenterol; 2004 Aug; 99(8):1490-6. PubMed ID: 15307866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peginterferon Alfa-2b and ribavirin for 12 versus 24 weeks in HCV infection.
    Borg BB; Hoofnagle JH
    N Engl J Med; 2005 Sep; 353(11):1182-3; author reply 1182-3. PubMed ID: 16162894
    [No Abstract]   [Full Text] [Related]  

  • 19. [Peginterferon-alpha and ribavirin combination therapy in chronic hepatitis C].
    Han KH; Yoon YH
    Korean J Hepatol; 2004 Jun; 10(2):81-7. PubMed ID: 15218341
    [No Abstract]   [Full Text] [Related]  

  • 20. Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection.
    Lagging M; Langeland N; Pedersen C; Färkkilä M; Buhl MR; Mørch K; Dhillon AP; Alsiö A; Hellstrand K; Westin J; Christensen P; Leutscher P; Norkrans G;
    Hepatology; 2008 Aug; 48(2):695. PubMed ID: 18666232
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.